Neurocrine biosciences announces fda approval of once-daily ongentys

Neurocrine biosciences announces fda approval of once-daily ongentys® (opicapone) as an add-on treatment for patients with parkinson's disease experiencing "off" episodes.neurocrine biosciences inc - plans to make ongentys available to patients later this year.neurocrine biosciences - data from trials showed that ongentys 50 mg significantly reduced "off" time from baseline to week 14 or 15 versus placebo.
NBIX Ratings Summary
NBIX Quant Ranking